Use of inhibitors of acid sphingomyelinase to treat acquired and inherited retinal degenerations
US10124008B2 · kind B2 · utility
1Cited by
0References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 22, 2015 |
| Grant date | Nov 13, 2018 |
| Priority date | — |
| Expiry date | Jun 22, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating retinal diseases is disclosed that includes the step of administering an effective amount of a composition including an ASMase inhibitor to a retinal disease patient, wherein at least one disease symptom is either lessened or progression of the symptom is delayed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.